Special Issue

ECM Code in Physiological and Pathological Processes

Message from the Guest Editor

This Special Issue, "ECM Code in Physiological and Pathological Processes", will mainly focus on the role of the extracellular matrix (ECM) during physiological tissue development and disease-state conditions. In this Special Issue, authors from the ECM field are invited to submit original or review articles regarding the following topics:

- Glycobiology in matrix pathobiology;
- Extracellular matrix "omics";
- Therapeutic approaches targeting ECM functionality;
- ECM-based advanced biomaterials;
- Bioinformatic approaches for better understanding of ECM impact;
- ECM-mediated immune response;
- Matrix enzymology and paracrine interactions;
- Cell-ECM interactions in matrix biology and pathology;
- Functional role of ECM macromolecules and their role in cellular signaling.

Guest Editor

Dr. Nikolaos A. Afratis

Laboratory of Biotechnology and Molecular Analysis, Department of Agricultural Development, Agrofood & Management of Natural Resources, National and Kapodistrian University of Athens Evripos Campus, 34400 Psachna, Greece

Deadline for manuscript submissions

closed (30 September 2023)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/126112

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).